6 курс / Кардиология / Показания_к_реваскуляризации_миокарда_Российский_cогласительный

231.Pocock S. J., Lansky A. J., Mehran R. et al. Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials // J. Am. Coll. Cardiol. – 2008. – Vol. 51. – P. 23–32.

232.Kedhi E., Joesoef K. S., McFadden E. et al. Second-generation everolimuseluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial // Lancet. – 2010. – Vol. 375. – P. 201–209.

233.Camenzind E., Wijns W., Mauri L. et al. Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation // Am. Heart J. – 2009. – Vol. 158. – P. 902–909.

234.Nordmann A. J., Bucher H., Hengstler P. et al. Primary stenting versus primary balloon angioplasty for treating acute myocardial infarction // Cochrane Database Syst. Rev. – 2005; CD005313.

235.Kastrati A., Dibra A., Spaulding C. et al. Meta-analysis of randomized trials on drug-eluting stents vs. baremetal stents in patients with acute myocardial infarction // Eur. Heart J. – 2007. – Vol. 28. – P. 2706–2713.

236.Brilakis E. S., Saeed B., Banerjee S. Drug-eluting stents in saphenous vein graft interventions: a systematic review // EuroIntervention. – 2010. – Vol. 5. – P. 722–730.

237.Daemen J., Wenaweser P., Tsuchida K. et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study // Lancet. – 2007. – Vol. 369. – P. 667–678.

238.Cook S., Ladich E., Nakazawa G. et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis // Circulation. – 2009. – Vol. 120. – P. 391–399.

239.Beijk M. A., Klomp M., Verouden N. J. et al. Genous endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study // Eur. Heart J. – 2010. – Vol. 31. – P. 1055–1064.

240.Maier L. S., Maack C., Ritter O., Bohm M. Hotline update of clinical trials and registries presented at the German Cardiac Society meeting 2008 (PEPCAD, Lokal-Tax, INH, German ablation registry, German device registry, KTRG.DE registry, DHR, Reality, SWEETHEART registry, ADMA, GERSHWIN) // Clin. Res. Cardiol. – 2008. – Vol. 97. – P. 356–363.

241.Serruys P. W., Ormiston J. A., Onuma Y. et al. A bioabsorbable everolimuseluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods // Lancet. – 2009. – Vol. 373. – P. 897–910.

242.Park S. J., Kim Y. H., Park D. W. et al. Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis // Circ. Cardiovasc. Interv. – 2009. – Vol. 2. – P. 167–177.

243.Wu X., Maehara A., Mintz G. S. et al. Virtual histology intravascular ultrasound analysis of non-culprit attenuated plaques detected by grayscale intravascular ultrasound in patients with acute coronary syndromes // Am. J. Cardiol. – 2010. – Vol. 105. – P. 48–53.

244.Montalescot G., White H. D., Gallo R. et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention // N. Engl. J. Med. – 2006. – Vol. 355. – P. 1006–1017.

160

245.Mehta S. R., Bassand J. P., Chrolavicius S. et al. Design and rationale of CURRENT-OASIS 7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-ele- vation acute coronary syndromes managed with an early invasive strategy // Am. Heart J. – 2008. – Vol. 156. – P. 1080–1088.

246.Wiviott S. D., Braunwald E., McCabe C. H. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes // N. Engl. J. Med. – 2007. – Vol. 357. – P. 2001–2015.

247.Wiviott S. D., Braunwald E., Angiolillo D. J. et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel–Thrombolysis in Myocardial Infarction 38 // Circulation. – 2008. – Vol. 118. – P. 1626–1636.

248.Wallentin L., Becker R. C., Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes // N. Engl. J. Med. – 2009. – Vol. 361. – P. 1045–1057.

249.Kastrati A., Mehilli J., Neumann F. J. et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial // JAMA. – 2006. – Vol. 295. – P. 1531–1538.

250.Mehta S. R., Granger C. B., Eikelboom J. W. et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial //

J.Am. Coll. Cardiol. – 2007. – Vol. 50. – P. 1742–1751.

251.Stone G. W., Ware J. H., Bertrand M. E. et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: oneyear results from the ACUITY trial // JAMA. – 2007. – Vol. 298. – P. 2497–2506.

252.Montalescot G., Wiviott S. D., Braunwald E. et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITONTIMI 38): double-blind, randomised controlled trial // Lancet. – 2009. – Vol. 373. – P. 723–731.

253.Cannon C. P., Harrington R. A., James S. et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomized double-blind study // Lancet. – 2010. – Vol. 375. – P. 283–293.

254.Huber K., Holmes D. R. Jr, van ’t Hof A. W. et al. Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial // Eur. Heart J. – 2010. – Vol. 31. – P. 1708–1716.

255.Stone G. W., Witzenbichler B., Guagliumi G. et al. Bivalirudin during primary PCI in acute myocardial infarction // N. Engl. J. Med. – 2008. – Vol. 358. –

P.2218–2230.

256.Yusuf S., Mehta S. R., Chrolavicius S. et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial // JAMA. – 2006. – Vol. 295. – P. 1519–1530.

257.Lip G. Y., Huber K., Andreotti F. et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary–a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) // Eur. Heart J. – 2010. – Vol. 31. – P. 1311–1318.

161

258.O’Donoghue M. L., Braunwald E., Antman E. M. et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a protonpump inhibitor: an analysis of two randomised trials // Lancet. – 2009. – Vol. 374. – P. 989–997.

259.Akerblom A., James S. K., Koutouzis M. et al. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) // J. Am. Coll. Cardiol. – 2010. – Vol. 56. – P. 470–475.

260.Zeymer U., Margenet A., Haude M. et al. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial // J. Am. Coll. Cardiol. – 2010. – Vol. 56. – P. 463–469.

261.King S. B. III, Smith S. C. Jr, Hirshfeld J. W. Jr et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 writing group to review new evidence and update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, writing on behalf of the 2005 Writing Committee // Circulation. – 2008. – Vol. 117. – P. 261–295.

262.Piepoli M. F., Corra U., Benzer W. et al. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation // Eur. J. Cardiovasc. Prev. Rehabil. – 2010. – Vol. 17. – P. 1–17.

263.Graham I., Atar D., Borch-Johnsen K. et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary // Eur. Heart J. – 2007. – Vol. 28. – P. 2375–2414.

264.International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes // Diabetes Care. – 2009. – Vol. 32. – P. 1327–1334.

265.Smith S. C. Jr, Allen J., Blair S. N. et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute //

J.Am. Coll. Cardiol. – 2006. – Vol. 47. – P. 2130–2139.

266.Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report // Circulation. – 2002. – Vol. 106. – P. 3143–3421.

267.Cannon C. P., Steinberg B. A., Murphy S. A. et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy //

J.Am. Coll. Cardiol. – 2006. – Vol. 48. – P. 438–445.

268.Duggal J. K., Singh M., Attri N. et al. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease // J. Cardiovasc. Pharmacol. Ther. – 2010. – Vol. 15. – P. 158–166.

269.Gibbons R. J., Abrams J., Chatterjee K. et al. ACC/AHA 2002 Guideline Update for the Management of Patients with Chronic Stable Angina–summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina) // Circulation. – 2003. – Vol. 107. – P. 149–158.

270.Cannon C. P., Braunwald E., McCabe C. H. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes // N. Engl. J. Med. – 2004. – Vol. 350. – P. 1495–1504.

162